目的 觀察連花清瘟膠囊聯(lián)合頭孢哌酮鈉舒巴坦鈉治療社區(qū)獲得性肺炎的臨床療效。方法 選取2016年1月—2016年12月海南醫(yī)學(xué)院第一附屬醫(yī)院接診的社區(qū)獲得性肺炎患者106例，隨機(jī)分成對(duì)照組和治療組，每組各53例。對(duì)照組靜脈滴注注射用頭孢哌酮鈉舒巴坦鈉，2 g加入生理鹽水250 mL，1次/12 h；治療組在對(duì)照組的基礎(chǔ)上口服連花清瘟膠囊，4粒/次，3次/d。兩組均連續(xù)治療10 d。評(píng)價(jià)治療后兩組患者臨床療效，同時(shí)比較治療前后兩組臨床癥狀體征和胸片改善情況以及白細(xì)胞計(jì)數(shù)（WBC）、中粒細(xì)胞百分比（N%）和高敏C反應(yīng)蛋白（hs-CRP）水平變化。結(jié)果 治療后，對(duì)照組和治療組總有效率分別為81.13%、92.45%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，治療組患者體溫恢復(fù)時(shí)間、咳嗽癥狀消失時(shí)間、濕性啰音體征消失時(shí)間均比對(duì)照組明顯縮短，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，對(duì)照組胸片改善總有效率為83.02%，顯著低于治療組的94.34%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組WBC、N%和hs-CRP指標(biāo)水平顯著低于治療前，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組上述指標(biāo)水平明顯好于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。結(jié)論 連花清瘟膠囊聯(lián)合頭孢哌酮鈉舒巴坦鈉可明顯改善社區(qū)獲得性肺炎患者臨床癥狀體征和胸片結(jié)果，不良反應(yīng)較少，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical effect of Lianhua Qingwen Capsules combined with cefoperazone sodium and sulbactam sodium in treatment of community acquired pneumonia. Methods Patients (106 cases) with community acquired pneumonia from January 2016 to December 2016 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group were iv administered with Cefoperazone Sodium and Sulbactam Sodium for injection, 2 g added into 250 mL normal saline, once every 12 h. Patients in the treatment group were po administered with Lianhua Qingwen Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 10 d. After treatment, clinical efficacy was evaluated, and the improvement of the clinical symptoms and chest X-ray, the levels of WBC, N%, and hs-CRP in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.13% and 92.45%, respectively, and there were differences between two groups (P < 0.05). After treatment, the body temperature recovery time, cough symptom, and wet rale disappearance time were significantly shorter than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the improvement of chest X-ray in the control group was 83.02%, which was significantly lower than 94.34% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the WBC, N%, and hs-CRP levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these indicators levels in treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Lianhua Qingwen Capsules combined with cefoperazone sodium and sulbactam sodium can obviously improve the clinical symptoms, signs and chest X-ray in treatment of community acquired pneumonia with less adverse reactions, which has a certain clinical application value.